Iowa deserves affordable healthcare.

The 340B program helps community health centers, hospitals, and other safety net buy prescription medications at lower prices so they can stretch their resources and better serve patients.

This means more people—especially those in rural or underserved areas—can get the care they need, like doctor visits, dental care, mental health support, maternal care, and affordable medicine.

The savings from 340B are reinvested into local healthcare services, making it a vital program that helps keep care accessible and affordable for everyone.

The Protect 340B Coalition aims to pass legislation in Iowa that upholds the original intent of the program, gives patients the freedom to choose which pharmacy they want to use, and allows for covered entities to invest in local healthcare.

What is the impact of 340B?

  • Ensures Local Control & Rural Access

    340B ensures that Iowans in rural and other areas were access to care is scarce get the medications they need locally, at an affordable price, all while supporting small businesses.

  • Taxpayer Value


    At no expense to taxpayers, 340B resources are invested into staff and facilities to improve care for patients.

  • Supports Working Families & Individuals

    Resources fund services for veterans, farmers, seniors, and low-income workers. Without access to the program, many patients will end up in more costly care like Emergency Rooms.

  • Addresses Rural Healthcare Issues

    340B resources are vital to rural healthcare sustainability. It allows for reinvestment in critical services like behavioral health, maternal care, cancer treatment, EMS, and mobile clinics.

Protecting the 340B Program means:

  • Preserving rural pharmacy access

  • Preserving patient access to affordable prescription drugs and healthcare services

  • Preventing higher healthcare costs to taxpayers

  • Supporting small business and keeping pharmacy revenue local

Big pharma is putting profits over patients.

  • In 2023 alone, 16 of the largest drug companies reported $684 billion in earnings.

    That is higher than the gross domestic product (GDP) of 88% of the countries in the world.

  • Big Pharma’s 10 highest-paid CEOs of 2024

    Uğur Şahin, BioNTech: $287 million

    David Ricks, Eli Lilly: $29.2 million

  • Quote Source